Infliximab (chimeric anti-tumour necrosis factor ?? monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial, The Lancet, vol.354, issue.9194, pp.1932-1939, 1999. ,
DOI : 10.1016/S0140-6736(99)05246-0
The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial, Arthritis & Rheumatism, vol.49, issue.6, pp.1451-1459, 2002. ,
DOI : 10.1002/art.10302
Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.64, issue.5, pp.704-707, 2005. ,
DOI : 10.1136/ard.2004.030452
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor ?? inhibitor infliximab, Arthritis & Rheumatism, vol.45, issue.12, pp.3782-3789, 2006. ,
DOI : 10.1002/art.22214
Double-blinded infliximab dose escalation in patients with rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.66, issue.9, pp.1233-1238, 2007. ,
DOI : 10.1136/ard.2006.065995
A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with rheumatoid arthritis: characterization of infliximab-resistant cases and PK-based modified therapy, Modern Rheumatology, vol.73, issue.2, pp.83-91, 2007. ,
DOI : 10.1002/art.20568
Infliximab concentration is predictive of control of disease activity and maintenance of treatment in rheumatoid arthritis, Ann Rheum Dis, issue.2, pp.67-177, 2008. ,
A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study, Rheumatology, vol.44, issue.4, pp.465-468, 2005. ,
DOI : 10.1093/rheumatology/keh494
Effectiveness of reducing infliximab dose interval in non-responder patients with refractory spondyloarthropathies. An open extension of a multicentre study, Rheumatology, vol.44, issue.12, pp.1555-1558, 2005. ,
DOI : 10.1093/rheumatology/kei085
Recommendations of the French Society for Rheumatology regarding TNF?? antagonist therapy in patients with rheumatoid arthritis, Joint Bone Spine, vol.74, issue.6, pp.627-637, 2007. ,
DOI : 10.1016/j.jbspin.2007.10.001
An Enzyme-Linked Immunosorbent Assay for Therapeutic Drug Monitoring of Infliximab, Therapeutic Drug Monitoring, vol.28, issue.2, pp.169-174, 2006. ,
DOI : 10.1097/01.ftd.0000189901.08684.4b
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease, New England Journal of Medicine, vol.348, issue.7, pp.601-608, 2003. ,
DOI : 10.1056/NEJMoa020888
Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease, Alimentary Pharmacology and Therapeutics, vol.94, issue.4, pp.463-473, 2001. ,
DOI : 10.1002/1529-0131(199910)42:10<2166::AID-ANR18>3.0.CO;2-K
Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis, Arthritis & Rheumatism, vol.86, issue.3, pp.711-715, 2006. ,
DOI : 10.1002/art.21671
Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies, JAMA, vol.295, issue.19, pp.2275-2285, 2006. ,
DOI : 10.1001/jama.295.19.2275
Immunogenicity of anti-TNF-alpha agents in autoimmune diseases, Clin Rev Allergy Immunol, 2009. ,
Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.68, issue.11, pp.1739-1745, 2009. ,
DOI : 10.1136/ard.2008.092833
Population Pharmacokinetics of Infliximab in Patients With Ankylosing Spondylitis, The Journal of Clinical Pharmacology, vol.26, issue.suppl 28, pp.681-695, 2008. ,
DOI : 10.1177/0091270008316886
Infliximab Pharmacokinetics in Inflammatory Bowel Disease Patients, Therapeutic Drug Monitoring, vol.PAP, pp.523-529, 2008. ,
DOI : 10.1097/FTD.0b013e318180e300
URL : https://hal.archives-ouvertes.fr/hal-00616549